Search
Pivotal Ruxolitinib Data Shows Promise for Patients with PV.
Polycythemia vera (PV) is a chronic, incurable blood cancer with limited treatment options. If uncontrolled, PV can cause serious cardiovascular complications, such as stroke and heart attack.
Harnessing new developments in genomics to improve outcome for children with poor prognosis leukemia
At the 19th Congress of the European Hematology Association (EHA), we will learn about the state-of-the-art in management of childhood AML.
Read moreAdvances from genome sequencing are paving the way to personalized treatment for leukemia and pre-leukemia
In acute myeloid leukemia (AML) our understanding of how modifications to DNA molecules that do not result in sequence change (i. e.
Read moreLeading Medical Organizations Join Forces Globally to Launch First-Ever World Thrombosis Day
“We must reduce the burden from thrombosis if we are to achieve the World Health Assembly’s global target of reducing mortality from premature non-communicable disease by 25 percent by 2025,” said Gary Raskob, Ph. D.
Read moreTreatment, medicine and hematology research: What patients want and doctors need (to know)
Jan Geissler, a Patient Advocate remarked about the Congress: “Over and above scientific updates, much can be achieved in partnership between hematologists and patients.
Read moreEuropean Hematologists will discuss breakthroughs in blood disorders in Milan, Italy - June 12-15, 2014
About the EHA Annual Congress
Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases of blood and their treatments.
Research must provide ‘more good news on outcomes’ while patients need simple and effective information
On behalf of EHA, professor Giovanni Martinelli and professor Theo de Witte spoke of their cutting edge research and the next steps in personalized medicine research in hematology.
Read moreSanquin Blood Supply will culture erythrocytes for transfusion purposes
ABO-Rh-D matched transfusions result in alloimmunisation in 3-5% of recipients. Once allo-immunized, it may become very difficult to find appropriate donor erythrocytes, especially when multiple antibodies or rare combinations of antibodies are present.
Read morePosition of EHA on the Harmonization of Training and Education in Europe
The challenge
Education and training are largely national competencies.
Position of EHA on Clinical Trials
The challenge
In Europe, the number of clinical trials is steadily decreasing. From 2007 to 2010, their number has decreased by some 20 percent from 5,028 to 4,193.